Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: A systematic review and network meta-analysis

Therapeutic Advances in Respiratory Disease

Volumn 10, Issue 2, 2016, Pages 89-104

  Schlueter, Max ^a   Gonzalez Rojas, N ^b   Baldwin, Michael ^b   Groenke, Lars ^b   Voss, Florian ^b   Reason, Tim ^a  

^a IQVIA   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

aclidinium formoterol; chronic obstructive pulmonary disease; glycopyrronium indacaterol; network meta analysis; tiotropium olodaterol; umeclidinium vilanterol

Indexed keywords

ACLIDINIUM BROMIDE; ACLIDINIUM BROMIDE PLUS FORMOTEROL FUMARATE; ACLIDINIUM PLUS FORMOTEROL; BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS SALMETEROL; CORTICOSTEROID; FLUTICASONE FUROATE PLUS SALMETEROL; FLUTICASONE FUROATE PLUS VILANTEROL; FORMOTEROL; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL PLUS TIOTROPIUM BROMIDE; PLACEBO; SALMETEROL; SALMETEROL PLUS TIOTROPIUM; TIOTROPIUM BROMIDE; UMECLIDINIUM PLUS VILANTEROL; UNCLASSIFIED DRUG; BRONCHODILATING AGENT; DRUG COMBINATION;

ARTICLE; BAYES THEOREM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; COMPARATIVE EFFECTIVENESS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TRANSITION DYSPNEA INDEX; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; DRUG EFFECTS; LUNG; NETWORK META-ANALYSIS; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BAYES THEOREM; BRONCHODILATOR AGENTS; DRUG COMBINATIONS; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MUSCARINIC ANTAGONISTS; NETWORK META-ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84960540618     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465815624612     Document Type: Article

References (71)

1. Aalbers R., Maleki-Yazdi M., Hamilton A., Waitere-Wijker S., Pivovarova A., Schmidt O., et al. (2012) Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD. Eur Respir J 40: 525s-526s.
2. Amaris (2013) Systematic literature review in the treatment of COPD with fixed-dose combination of bronchodilators. Review protocol.
3. Anzueto A., Decramer M., Kaelin T., Richard N., Tabberer M., Harris S., et al. (2013) The efficacy and safety of umeclidinium/vilanterol compared with tiotropium or vilanterol over 24 weeks in subjects with COPD. Am J Respir Crit Care Med 187: A4268.
4. Bateman E., Ferguson G., Barnes N., Gallagher N., Green Y., Henley M., et al. (2013) Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 42: 1484-1494.
5. Bateman E., Singh D., Smith D., Disse B., Towse L., Massey D., et al. (2010a) Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 5: 197-208.
6. Bateman E., Tashkin D., Siafakas N., Dahl R., Towse L., Massey D., et al. (2010b) A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med 104: 1460-1472.
7. Boehringer Ingelheim International GmbH (2005) Spiriva® Assessment of FEV1 (SAFE). The effect of inhaled tiotropium bromide (18 mcg once daily) on the change in FEV1 during long-term treatment in patients with COPD. A one-year parallel group, double-blind, randomised, placebo-controlled study. Ingelheim am Rhein: Boehringer Ingelheim International GmbH.
8. Buhl R., Maltais F., Abrahams R., Bjermer L., Derom E., Ferguson G., et al. (2015) Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 45: 969-979.
9. Casaburi R., Mahler D., Jones P., Wanner A., San P., ZuWallack R., et al. (2002) A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19: 217-224.
10. D'Urzo A., (2014) Twice-daily aclidinium bromide/formoterol fumarate fixed-dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. In 110th International Conference of the American Thoracic Society.
11. D'Urzo A., Mergel V., Leselbaum A., Caracta C., (2013) Efficacy and safety of fixed-dose combination aclidinium bromide/formoterol fumarate in patients with COPD: Results from the AUGMENT COPD trial. Chest 144: 1025A.
12. D'Urzo A., Rennard S., Kerwin E., Mergel V., Leselbaum A., Caracta C., (2014a) Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res 15: 123.
13. D'Urzo A., Rennard S., Mergel V., Garcia Gil E., Leselbaum A., Caracta C., (2014b) The Augment COPD trial: Efficacy and safety of a fixed-dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest 145: 426A.
14. Dahl R., Chapman K., Rudolf M., Mehta R., Kho P., Alagappan V., et al. (2013) Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 107: 1558-1567.
15. Decramer M., Anzueto A., Kerwin E., Kaelin T., Richard N., Crater G., et al. (2014) Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2: 472-486.
16. Decramer M., Anzueto A., Kerwin E., Richard N., Crater G., Tabberer M., et al. (2013a) Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or triotopium in COPD. In European Respiratory Society (ERS) Annual Congress.
17. Decramer M., Celli B., Kesten S., Lystig T., Mehra S., Tashkin D., (2009) Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 374: 1171-1178.
18. Decramer M., Wedzicha J., Ficker J., (2013b) Once-daily QVA149 improves health-related quality of life in patients with severe to very severe COPD: The SPARK Study. Chest 187: A4257.
19. Decramer M., Wedzicha J., Ficker J., (2013c) Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: the SPARK study. Eur Respir J 42 (Suppl. 57): P756.
20. Decramer M., Wedzicha J., Sandstrom T., Niewohner D., Fowler Taylor A., D'Andrew P., et al. (2013d) Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: The SPARK study. Chest 187: A1479.
21. Dias S., Welton N., Sutton A., Ades A., (2011a) NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. Available at: http://www.nicedsu.org.uk.
22. Dias S., Welton N., Sutton A., Caldwell D., Lu G., Ades A., (2011b) NICE DSU Technical Support Document 4: Inconsistency in networks of evidence based on randomised controlled trials. NICE Decision Support Unit.
23. Donohue J., Fogarty C., Lotvall J., Mahler D., Worth H., Yorgancioglu A., et al. (2010) Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 182: 155-162.
24. Donohue J., Maleki-Yazdi M., Kilbride S., Mehta R., Kalberg C., Church A., (2013) Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 107: 1538-1546.
25. Donohue J., Menjoge S., Kesten S., (2003) Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 97: 1014-1020.
26. Donohue J., van Noord J., Bateman E., Langley S., Lee A., Witek T. Jr, et al. (2002) A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122: 47-55.
27. Dusser D., Bravo M., Iacono P., (2006) The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 27: 547-555.
28. European Medicines Agency (2014) Assessment Report. Duaklir Genuair. International non-proprietary name: Aclidinium bromide/ Formoterol fumarate dihydrate. Procedure No. EMEA/H/C/003745/0000. London: European Medicines Agency.
29. 1 time profile of olodaterol once daily (QD) via Respimat(R) and formoterol twice daily (BID) via Aerolizer(R) in patients with COPD: results from two 6-week studies. Chest 144: 749A.
30. Ferguson G., Feldman G., Hofbauer P., Hamilton A., Allen L., Korducki L., et al. (2013) Lung function efficacy of olodaterol QD delivered via Respimat(R) in COPD patients: Results from two 48-week studies. Eur Respir J 42: 5s.
31. Ficker J., Wedzicha J., Decramer M., (2013a) QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: the SPARK study. Eur Respir J 42 (Suppl. 57): P3639.
32. Ficker J., Wedzicha J., Decramer M., (2013b) QVA149 reduced COPD exacerbation rate in various subgroups of patients: the SPARK study. Eur Respir J 42 (Suppl. 57): 182.
33. Fuso L., Mores N., Valente S., Malerba M., Montuschi P., (2013) Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem 20: 1477-1495.
34. Global Initiative for Chronic Obstructive Lung Disease (2015) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease.
35. Halbert R., Natoli J., Gano A., Badamgarav E., Buist A., Mannino D., (2006) Global burden of COPD: systematic review and meta-analysis. Eur Respir J 28: 523-532.
36. Higgins J., Green S., (2011) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated 2011 ]. The Cochrane Collaboration.
37. Hoaglin D., Hawkins N., Jansen J., Scott D., Itzler R., Cappelleri J., (2011) Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 14: 429-437.
38. Hodder R., Kesten S., Menjoge S., Viel K., (2007) Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis 2: 157-167.
39. Huisman E., Cockle S., Ismaila A., Karabis A., Punekar Y., (2015) Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis. Int J Chron Obstruct Pulmon Dis 10: 1863-1881.
40. Jansen J., Fleurence R., Devine B., Itzler R., Barret A., Hawkins N., (2011) Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14: 417-428.
41. Jansen J., Naci H., (2013) Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med 11: 159.
42. Jansen J., Trikalinos T., Cappelleri J., Daw J., Andes S., Eldessouki R., et al. (2014) Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 17: 157-173.
43. Kerwin E., Hebert J., Gallagher N., Martin C., Overend T., Alagappan V., et al. (2012) Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 40: 1106-1114.
44. Koch A., Paggiaro P., Hamilton A., Hart L., Korducki L., De Salvo M., et al. (2013a) Symptomatic benefit of olodaterol QD delivered via Respimat® versus placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies. Eur Respir J 42: 145s.
45. Koch A., Pizzichini E., Hamilton A., Hart L., Korducki L., De Salvo M., et al. (2013b) Lung function efficacy of olodaterol QD delivered via Respimat® versus placebo and formoterol BID in patients with COPD: Two 48-week studies. Eur Respir J 42: 146s.
46. 1 time profile of olodaterol QD delivered via Respimat(R) in COPD: Results from two 6-week studies. Eur Respir J 42: 982s.
47. Lunn D., Thomas A., Best N., Spiegelhalter D., (2000) WinBUGS-A Bayesian modelling framework: concepts, structure, and extensibility. Statist Comput 10: 325-337.
48. Maleki-Yazdi M., Kaelin T., Richard N., Zvarich M., Church A., (2014) Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med 108: 1752-1760.
49. Malerba M., Morjaria J., Radaeli A., (2014) Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD-role of umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis 9: 687-695.
50. Malerba M., Radaeli A., Morjaria J., (2012) Therapeutic potential for novel ultra long-acting beta2-agonists in the management of COPD: biological and pharmacological aspects. Drug Discov Today 17: 496-504.
51. Maltais F., Beck E., Webster D., Maleki-Yazdi M., Seibt J., Arnoux A., (2010) Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients. Eur Respir J 36 (Suppl. 54): 1014s.
52. Maltais F., Singh S., Donald A., Crater A., Church A., Goh A., et al. (2013) Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: two randomised clinical trials. In European Respiratory Society Annual Congress.
53. Mosenifar Z., (2015) Chronic Obstructive Pulmonary Disease Treatment & Management. Available at: http://emedicine.medscape.com/article/297664-treatment
54. National Institute for Health and Care Excellence (2013) Guide to the methods of technology appraisal. National Institute for Health and Care Excellence.
55. Niewoehner D., Rice K., Cote C., Paulson D., Cooper J. Jr, Korducki L., et al. (2005) Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 143: 317-326.
56. Oba Y., Sarva S., Dias S., (2015) Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. PII: thoraxjnl-2014-206732. DOI: 10.1136/thoraxjnl-2014-206732.
57. Powrie D., Wilkinson T., Donaldson G., Jones P., Scrine K., Viel K., et al. (2007) Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 30: 472-478.
58. Seemungal T., Donaldson G., Bhowmik A., Jeffries D., Wedzicha J., (2000) Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161: 1608-1613.
59. Singh D., Jones P., Bateman E., Korn S., Serra C., Molins E., et al. (2014) Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med 14: 178.
60. Tashkin D., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359: 1543-1554.
61. Tonnel A., Perez T., Grosbois J., Verkindre C., Bravo M., Brun M., (2008) Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis 3: 301-310.
62. Troosters T., Celli B., Lystig T., Kesten S., Mehra S., Tashkin D., et al. (2010) Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 36: 65-73.
63. Troosters T., Sciurba F., Decramer M., Siafakas N., Klioze S., Sutradhar S., et al. (2014) Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. NPJ Prim Care Respir Med 24: 14003.
64. Vogelmeier C., Kardos P., Harari S., Gans S., Stenglein S., Thirlwell J., (2008) Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 102: 1511-1520.
65. Wedzicha J., (2013) Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: The SPARK Study. Amer J Respir Crit Care Med 187: A2429.
66. Wedzicha J., Decramer M., Ficker J., (2013a) Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: the SPARK study. Eur Respir J 42 (Suppl. 57): 181.
67. Wedzicha J., Decramer M., Ficker J.H., (2013b) Dual bronchodilation with QVA149 reduces COPD exacerbations: The SPARK study. Amer J Respir Crit Care Med 187: A2428.
68. Wedzicha J., Decramer M., Ficker J., Niewoehner D., Sandstrom T., Taylor A., et al. (2013c) Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet. Respir Med 1: 199-209.
69. Welton N., Caldwell D., Adamopoulos E., Vedhara K., (2009) Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. Am J Epidemiol 169: 1158-1165.
70. Wise R., Anzueto A., Cotton D., Dahl R., Devins T., Disse B., et al. (2013) Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 369: 1491-1501.
71. World Health Organization (2014) Burden of COPD. Geneva: World Health Organization.